



Daily Update

Thursday 4th March 2021

This daily update contains important information for community pharmacy teams about the ongoing response to the COVID-19 pandemic.

In today's update: PSNC summary briefing on the Integration and Innovation DHSC White Paper; PSNC and LPC joint MP briefing events; Repaglinide supply disruption alert.

PSNC summary briefing on the Integration and Innovation DHSC White Paper

PSNC has produced a briefing that summarizes the Department for Health and Social Care's (DHSC) recently published Integration and Innovation White paper.

[Read the DHSC's Integration and Innovation White paper](#)

[Read PSNC's summary briefing](#)

PSNC and LPC joint MP briefing events

PSNC and LPCs joined forces today in the latest of our joint MP briefing events. These events have been bringing MPs from across the political spectrum together with their local LPCs to hear about the work community pharmacies are doing, and the challenges they are facing at both local and national levels.

The events form a part of PSNC's overall strategy to try to ensure the Government recognises the work that community pharmacies have done throughout the pandemic and writes off pharmacies' COVID-19 emergency loans. The events are also supporting LPCs' local engagement work.

[Learn more about PSNC's call for pharmacies C-19 loans to be written off](#)

Any LPCs who have not yet taken part in one of the MP briefing events but would like to arrange one should email Jessica.ferguson@psnc.org.uk

Supply Disruption Alert: Repaglinide 1mg and 2mg tablets

The Department of Health and Social Care (DHSC) has issued a medicine supply disruption alert for **Repaglinide 1mg and 2mg tablets**.

Viatrix is currently out of stock of repaglinide 1mg and 2mg tablets until early May 2021 due to regulatory issues. Rivopharm UK Limited is out of stock due to manufacturing issues and is unable to confirm a resupply date.

[Learn more about this supply disruption alert](#)

Have you seen our latest FAQs?

PSNC's website has a large number of answers to queries posed by pharmacy contractors, their teams and LPCs; these are updated on a regular basis. Recent additions include:

Q. Do the three stages of the Discharge Medicines Service (DMS) have to be provided in strict order?

No. The three stages of the service could occur in parallel, depending on the timing of the referral being received by the pharmacy and the patient's individual circumstances. Normally stage 3 (the patient consultation) will occur when the first post-discharge prescription is received – this is usually one week to one-month post-discharge, dependent on the number of medicines supplied by the hospital at discharge. However, if the patient contacts the pharmacy in advance of the first post-discharge prescription being received, it may be deemed appropriate to provide stage 3 at that time. In that circumstance, there may be a need for a further discussion with the patient when the first prescription is received if issues are spotted on that prescription, which needs to be clarified with or communicated to the patient.

Q. Where a pharmacy receives a discharge referral from a hospital, can the pharmacy offer the New Medicine Service (NMS) to the patient as well?

DMS provides funding for the pharmacist or pharmacy technician to undertake a discussion (taking a shared decision-making approach) with the patient to ensure they understand their medicines regimen, including any changes made while being treated by the NHS trust; that is stage three of the service. Normally this would occur when the first post-discharge prescription is received. Where appropriate, other services which form part of the Community Pharmacy Contractual Framework can also be provided.

The New Medicine Service (NMS) could be offered if *clinically appropriate* if the patient *would get additional benefit from the provision of the service*, provided the medication is one listed as included in the NMS and the patient condition or therapy area the medication is prescribed for is one on the scheduled list.

Keep up-to-date on COVID-19 with our hub page: psnc.org.uk/coronavirus

Pharmaceutical Services Negotiating Committee



RSS

LinkedIn

Twitter

Facebook

14 Hosier Lane, London, EC1A 9LQ
Tel: 0203 1220 810 | Email: info@psnc.org.uk